World Allergy Organization Journal最新文献

{"title":"Evaluation of Lactococcus lactis carrying active For t 2 protein in immunotherapy for Forcipomyia taiwana allergy in mice","authors":"Mey-Fann Lee PhD ,&nbsp;Yi-Hsing Chen MD, PhD ,&nbsp;Chu-Hui Chiang PhD ,&nbsp;Chi-Sheng Wu MS ,&nbsp;Nancy M. Wang PhD","doi":"10.1016/j.waojou.2025.101073","DOIUrl":"10.1016/j.waojou.2025.101073","url":null,"abstract":"<div><h3>Background</h3><div><em>Forcipomyia taiwana</em> (Diptera: Ceratopogonidae) allergy is Taiwan's most prevalent biting insect allergy. Our previous studies identified and cloned major <em>F. taiwana</em> allergens For t 2 and determined its strong immunogenicity to human fibroblasts. This study investigated whether oral administration of food-grade <em>Lactococcus lactis</em> containing For t 2 ameliorated midge-allergic symptoms in a mouse model.</div></div><div><h3>Methods</h3><div>BALB/c mice, divided into viable, sonicated, and autoclaved groups, were fed with <em>L. lactis</em>-For t 2 5 times weekly for 4 weeks. Immune molecules related to allergies in serum were analyzed and 16S rRNA profiles of fecal samples were compared.</div></div><div><h3>Results</h3><div>The results revealed administration of <em>L. lactis</em>-For t 2 significantly decreased the level of total IgE and ameliorated midge allergen-challenge-induced scratch bouts found in the viable and sonicated groups, but not the autoclaved group. The sonicated group showed a significant reduction in IL-4, IL-13, IL-17, MCP-1, and TNF-α levels. Its effect was comparable to that of the viable group and was even more pronounced in reducing IL-9 expression. Further, we performed a comprehensive analysis of 16S rRNA profiles corresponding to fecal samples. Clostridiaceae and Clostridium were the dominant family and genus in the autoclaved group, whereas Duncaniella and Kineothrix were the dominant genus in the sonicated and viable groups, respectively.</div></div><div><h3>Conclusions</h3><div>The results imply that mucosal allergen-specific immunotherapy of <em>L. lactis</em> For t 2 is a better cost-effective alternative to conventional subcutaneous allergen-specific immunotherapy. This study shows that non-viable <em>L. lactis</em>-derived For t 2 active protein may be a promising therapeutic for treating midge allergy.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101073"},"PeriodicalIF":3.9,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's","authors":"Jonathan A. Bernstein MD ,&nbsp;Ignacio Ansotegui MD, PhD ,&nbsp;Riccardo Asero MD ,&nbsp;Aleena Banerji MD ,&nbsp;Stephen Betschel HBSc, MD ,&nbsp;Timothy Craig DO ,&nbsp;José Luis García-Abujeta MD ,&nbsp;René Maximiliano Gómez MD, PhD ,&nbsp;Anete S. Grumach MD, PhD ,&nbsp;Michihiro Hide MD, PhD ,&nbsp;David M. Lang MD ,&nbsp;Michael Levin MD, PhD ,&nbsp;Hilary J. Longhurst PhD ,&nbsp;Marcus Maurer MD ,&nbsp;Mario Morais-Almeida MD ,&nbsp;Dinh Nguyen Van MD, PhD ,&nbsp;Helena Pité MD, PhD ,&nbsp;Marc A. Riedl MD ,&nbsp;María Isabel Rojo Gutiérrez MD ,&nbsp;Sarbjit S. Saini MD ,&nbsp;Torsten Zuberbier MD, PhD","doi":"10.1016/j.waojou.2025.101068","DOIUrl":"10.1016/j.waojou.2025.101068","url":null,"abstract":"<div><div>Chronic spontaneous urticaria (CSU), with or without angioedema, is heterogeneous and comprised of different endotypes and phenotypes. Because acute urticaria will mostly resolve spontaneously, routine testing and laboratory evaluation is not required unless supported by the clinical history or physical examination. With the advent of omalizumab, there has been a surge of interest in identifying biomarkers that could predict response to this treatment. In the process of investigating biomarkers as prognosticators, several CSU phenotypes and endotypes have emerged, which have made it evident that novel therapies targeting non-IgE mechanistic pathways are needed to control symptoms in patients unresponsive to the currently recommended therapies by the most recent international guidelines. The current data support peripheral eosinophils, autoantibodies against IgE or FcεRI α subunit measured by basophil histamine release assays, total IgE levels and IgG autoantibodies against thyroid peroxidase (TPO) as specific markers to differentiate type 1 autoimmune (autoallergic) CSU from type 2b autoimmune CSU before starting treatment especially with omalizumab. These markers have been included as exploratory endpoints in many clinical trials investigating novel therapies or for repurposing existing biologics to determine responders and non-responders, but these data are not completely clear at this time. Therefore, further randomized controlled studies and real-world studies are needed to demonstrate more conclusively the utility of ordering these tests in CSU patients when they initially present or when it is determined they are not responsive to high dose second generation H1-antihistamines (SGAH) before they can be included in evidence-based CSU guidelines. This review examines the value of obtaining diagnostic tests in the initial evaluation of CSU patients to predict treatment response.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101068"},"PeriodicalIF":3.9,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144242315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mendelian randomization analysis reveals causal relationship between allergic diseases and influenza","authors":"Hui Li BSc ,&nbsp;Yanping Zong BSc ,&nbsp;Lei He BSc ,&nbsp;Yujie Sun BSc ,&nbsp;Weibing Shi MD ,&nbsp;Jinchen Guo MD","doi":"10.1016/j.waojou.2025.101077","DOIUrl":"10.1016/j.waojou.2025.101077","url":null,"abstract":"<div><h3>Background</h3><div>Allergic diseases and influenza share similar genetic backgrounds and pathophysiological mechanisms. Observational studies have established a correlation between these 2 conditions; however, the precise direction of the causal relationship remains unclear. This Mendelian randomization (MR) study aims to evaluate the causal relationship between allergic diseases and influenza.</div></div><div><h3>Materials and methods</h3><div>This study utilized summary statistical data from genome-wide association studies (GWAS) and employed the two-sample MR method to comprehensively analyze the causal relationships between allergic diseases (asthma, hay fever, eczema), atopic dermatitis (AD), hay fever or allergic rhinitis (AR), and different types of influenza (including all influenza, regular influenza excluding pneumonia, and severe influenza that encompasses both influenza and pneumonia) using genetic factors as instrumental variables. The analysis primarily relied on the inverse variance weighted random effects model (IVW-RE).</div></div><div><h3>Results</h3><div>The IVW-RE analysis revealed significant correlations between allergic diseases (asthma, hay fever, or eczema) and both all influenza and severe influenza (influenza and pneumonia). Additionally, AR (hay fever or allergic rhinitis) was associated with both all influenza and regular influenza (excluding pneumonia). Furthermore, a significant correlation was found between asthma and severe influenza (influenza and pneumonia). However, there is no evidence to support a causal relationship between AD and influenza.</div></div><div><h3>Conclusion</h3><div>The results of this MR study support a causal relationship between allergic diseases, asthma, and influenza, including severe influenza. This finding suggests that allergic diseases and asthma are significant risk factors for influenza. Additionally, this study provides high-quality causal evidence that can inform clinical practices aimed at preventing the onset of influenza, particularly in populations with respiratory allergies and asthma.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101077"},"PeriodicalIF":3.9,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144229916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of prenatal vitamin D supplementation on respiratory and allergy-related outcomes in children: A systematic review and meta-analysis of randomized controlled trials","authors":"Qin Li BSc ,&nbsp;Xiaoshuang Xu BSc ,&nbsp;Ying Liu MD ,&nbsp;Shao Yin MD ,&nbsp;Qian Hu MSc ,&nbsp;Qiang Ji MSc ,&nbsp;Yue Zhong MSc ,&nbsp;Fengya Zhu MD","doi":"10.1016/j.waojou.2025.101075","DOIUrl":"10.1016/j.waojou.2025.101075","url":null,"abstract":"<div><h3>Background</h3><div>Vitamin D is critical for immune regulation and respiratory health, yet its supplementation during pregnancy shows inconsistent results in preventing respiratory and allergy-related outcomes in children. This systematic review and meta-analysis aim to evaluate the impact of maternal vitamin D supplementation on respiratory tract infections (RTI), asthma, wheezing, eczema, and allergy in offspring.</div></div><div><h3>Methods</h3><div>A comprehensive search was performed in PubMed, Embase, Web of Science, Cochrane Library up to December 2024. We included randomized controlled trials (RCTs) examining the effects of prenatal vitamin D supplementation on respiratory and allergy-related outcomes in children. The GRADE approach was applied to assess the quality of evidence, and the Cochrane risk-of-bias tool was used to evaluate study quality.</div></div><div><h3>Results</h3><div>Seven RCTs were included (3958 mother-infant pairs). Prenatal vitamin D supplementation did not significantly reduce RTI in children compared to controls (RR = 1.018, 95% CI: 0.965 to 1.074, p = 0.514). Similarly, no significant effects were observed for asthma (RR = 0.395, 95% CI: 0.670 to 1.308, p = 0.699), wheezing (RR = 0.824, 95% CI: 0.826 to 1.089, p = 0.174), eczema (RR = 0.954, 95% CI: 0.826 to 1.102, p = 0.522), allergic conditions (RR = 0.938, 95% CI: 0.841 to 1.047, p = 0.255), or IgE positivity (RR = 0.942, 95% CI: 0.736 to 1.207, p = 0.639). Subgroup analyses showed no significant effect modification based on control group supplementation or follow-up duration.</div></div><div><h3>Conclusion</h3><div>There is moderate-quality evidence suggesting that prenatal vitamin D supplementation has minimal or no significant effect on reducing respiratory tract infections and allergy-related outcomes in children.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101075"},"PeriodicalIF":3.9,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144230093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the awareness of pediatric residents of anaphylaxis diagnosis through clinical scenarios","authors":"Tülay Tuğçe Kutsal Gültekin M.D. ,&nbsp;Ayşe Gökçe Kutsal M.D. ,&nbsp;Gökhan Yörüsün M.D. ,&nbsp;Ahmet Selmanoğlu M.D. ,&nbsp;Kaan Çelebier M.D. ,&nbsp;Zeynep Şengül Emeksiz ,&nbsp;Emine Dibek Mısırlıoğlu","doi":"10.1016/j.waojou.2025.101076","DOIUrl":"10.1016/j.waojou.2025.101076","url":null,"abstract":"<div><h3>Introduction</h3><div>Anaphylaxis is an acute onset, life-threatening systemic hypersensitivity reaction requiring urgent medical intervention. Early recognition and appropriate treatment of anaphylaxis are crucial for patient survival. This study aims to assess the awareness of pediatric residents regarding the diagnostic criteria, differential diagnosis, and appropriate treatment approaches for anaphylaxis.</div></div><div><h3>Materials and methods</h3><div>Active pediatric residents volunteering in participating in the study were included. Participants were given a questionnaire consisting of 10 clinical scenarios assessing diagnostic criteria and 15 questions evaluating professional experience and knowledge.</div></div><div><h3>Results</h3><div>A total of 198 pediatric residents were included in the study. The average clinical working experience of the participants was 18 months. On average, participants answered 7.3 out of 10 clinical scenario questions correctly (min-max: 3–10). In the clinical scenario describing a 2-year-old patient with a history of anaphylaxis to milk-based formula, the patient developed coughing and wheezing after entering the kitchen while the mother was boiling milk. The patient had a respiratory rate of 52/min, SpO₂ of 90%, and bilateral wheezing. This case, which involved no ingestion and presented only with signs of bronchospasm, was the scenario that participants found most challenging. While 64.1% of the participants classified it as anaphylaxis, 35.9% identified that the clinical presentation did not meet the diagnostic criteria for anaphylaxis. Similarly, the scenario involving a 17-year-old patient with acute rheumatic fever who developed syncope 5 min after receiving a benzathine penicillin injection and presented with confusion, heart rate of 58 bpm, blood pressure of 80/50 mmHg, respiratory rate of 38 breaths/min, SpO2 of 95%, and sinus bradycardia on ECG, was the least correctly identified as vasovagal syncope in terms of a differential diagnosis of anaphylaxis (33.8%). The results indicated that pediatric residents were less successful in diagnosing anaphylaxis in cases without skin/mucosal involvement and in drug/venom-related anaphylaxis cases. When both scenario-based and knowledge-based questions were considered, residents in their final 2 years and those who had received specialist training demonstrated significantly higher overall correct response rates (p &lt; 0.001, p = 0.002). Epinephrine was selected as the first-line treatment in 99.5% of cases; 81.3% of participants correctly identified the dosage, 97.5% the route of administration, and 89.4% the site of administration.</div></div><div><h3>Conclusion</h3><div>In our country, the emergency treatment and follow-up of pediatric patients experiencing anaphylaxis are mostly carried out by pediatric specialists. Therefore, the education and training on the diagnosis and emergency management of anaphylaxis, a pediatric emergency,","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101076"},"PeriodicalIF":3.9,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144229917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR)","authors":"Florence Schleich MD, PhD ,&nbsp;Désirée Larenas-Linnemann MD, FAAAAI, Dist.Intl.FACAAI ,&nbsp;Alan Altraja MD, PhD ,&nbsp;Luis Pérez de Llano MD, PhD ,&nbsp;Konstantinos Kostikas MD, PhD, FERS ,&nbsp;Mohsen Sadatsafavi MD, PhD ,&nbsp;Arnaud Bourdin MD, PhD ,&nbsp;Roy Alton Pleasants PharmD ,&nbsp;Mark Hew MBBS, PhD, FRACP ,&nbsp;Wenjia Chen PhD ,&nbsp;Libardo Jiménez-Maldonado MD ,&nbsp;Simon Couillard MD, MSc ,&nbsp;Charlotte Suppli Ulrik MD, DMSc ,&nbsp;Adeeb A. Bulkhi MD, MS ,&nbsp;Ming-Ju Tsai MD, PhD ,&nbsp;George C. Christoff MD, MPH, PhD ,&nbsp;Nikolaos G. Papadopoulos MD, PhD, FRCP ,&nbsp;Paul E. Pfeffer MRCP(UK), PhD ,&nbsp;Dermot Ryan MD, FRCGP ,&nbsp;Celine Bergeron MD, FRCPC, MSc ,&nbsp;David B. Price FRCGP","doi":"10.1016/j.waojou.2025.101066","DOIUrl":"10.1016/j.waojou.2025.101066","url":null,"abstract":"<div><h3>Background</h3><div>Asthma characterization using blood eosinophil count (BEC) (among other biomarkers and clinical indices) is recommended in severe asthma (SA), but the masking effect of oral corticosteroids (OCS), makes this challenging.</div></div><div><h3>Aim</h3><div>Our aim was to explore the effect of OCS use (both intermittent [iOCS] and long-term [LTOCS]) prior to biologic initiation on SA phenotype and biomarker profile in real-life and to characterize the burden of SA among patients prescribed LTOCS by biomarker profile.</div></div><div><h3>Methods</h3><div>This was a registry-based cohort study, including data from 23 countries collected between 2003 and 2023 and shared with the Internatonal Severe Asthma Registry (ISAR). Patients with SA were categorized into 3 cohorts, those with: (i) no prescription for OCS, (ii) prescription(s) for iOCS (ie, ≤90 days in previous 12-months, usually short courses for exacerbations), and (iii) prescriptions for LTOCS (ie, &gt;90 days in previous 12-months). Biomarker distribution (ie, BEC, fractional exhaled nitric oxide [FeNO], and total Immunoglobulin E [IgE]) were quantified in the year prior to biologic initiation in patients with SA according to OCS prescription pattern. Phenotypes were characterized for those prescribed LTOCS according to BEC cut-off (&lt;150 and ≥ 150 cells/μL).</div></div><div><h3>Results</h3><div>Of 4305 patients included, 5.0% (n = 215), 54.1% (n = 2330) and 40.9% (n = 1760) were prescribed no OCS, iOCS, and LTOCS, respectively. The BEC distribution varied by prescription pattern and LTOCS dose (&lt;5 mg to ≥20 mg/day); BEC was &lt;150 cells/μL in 28.6% (n = 369/1288) of LTOCS patients, compared to 19.5% (n = 284/1460) of iOCS patients and 14.0% (n = 21/150) of those in the no OCS group. Median BEC was also significantly lower in the LTOCS versus the iOCS group (310 vs 400 cells/μL; p &lt; 0.001). A similar pattern was noted for IgE, but not FeNO. Among LTOCS patients with BEC &lt;150 cells/μL, 39.9% experienced ≥4 exacerbations, 75.1% had uncontrolled asthma symptoms and 55.9% had evidence of persistent airflow obstruction (compared with 40.9%, 76.2% and 59.5% of those with BEC ≥150 cells/μL, respectively).</div></div><div><h3>Conclusions</h3><div>OCS, whether prescribed intermittently or long term, affect BEC distribution potentially leading to heightened risk of phenotype misclassification and influencing subsequent treatment decisions. FeNO appears to be less susceptible to OCS-induced suppression. Disease burden was high for those in the LTOCS group and was high independent of dose and BEC. Our findings highlight the importance of considering OCS use, even intermittent use, when characterizing SA, and suggests the need for earlier phenotyping and alternative treatment strategies for LTOCS patients with low BEC.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101066"},"PeriodicalIF":3.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144205623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergic-related skin diseases: Global disease burden from 1990 to 2021 and future trends","authors":"Xiao Tang MD ,&nbsp;Li Lin MD ,&nbsp;Fangning Yu MD,&nbsp;Yizhao Ma MM,&nbsp;Zeyu Liu MM,&nbsp;Xuying Xu MD","doi":"10.1016/j.waojou.2025.101072","DOIUrl":"10.1016/j.waojou.2025.101072","url":null,"abstract":"<div><h3>Background</h3><div>Allergic-related skin diseases, including atopic dermatitis (AD), urticaria, and contact dermatitis (CD), are significant global public health challenges. Currently, there is a lack of systematic analysis of allergic-related skin diseases globally.</div></div><div><h3>Methods</h3><div>This study aimed to quantify the global burden of AD, CD, and urticaria and evaluate their global epidemiology patterns. The Global Burden of Diseases (GBD) database was used to assess incidence, prevalence, and disability-adjusted life years (DALYs) for these allergic-related skin diseases. Additionally, the Bayesian Age-Period-Cohort (BAPC) model was employed to predict disease burden for the next 15 years.</div></div><div><h3>Results</h3><div>From 1990 to 2021, cases of AD, CD, and urticaria rose steadily. In 2021, AD prevalence reached 129 million, a 20.02% increase from 1990. However, average annual percentage change (AAPC) values for the age-standardized prevalence rate (ASPR) of AD declined constantly (AAPC = −0.28). CD had the highest incidence, with 253 million new cases in 2021, though AAPC for ASPR of CD showed minimal changes. AD and urticaria peaked in early life, while CD peaked at ages 75–79. Moreover, AD had the strongest positive correlation with the Socio-demographic Index (SDI) (<em>p</em> = 2.2e-16, ρ = 0.626). AD, CD, and urticaria show the highest age-standardized rate in high, middle, and low-middle SDI regions, respectively, with all 3 conditions declining in high SDI. Health inequality analysis showed AD's burden is now more evenly distributed across SDI groups, while the global burden gap for urticaria and CD change limitedly.</div></div><div><h3>Conclusion</h3><div>Although the global disease burden of allergic-related skin diseases continues to rise, the overall age-standardized rates of AD have steadily declined and are projected to decrease further. In contrast, CD and urticaria require increased attention.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101072"},"PeriodicalIF":3.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of three-bag and single-bag protocols in rapid drug desensitization with chemotherapeutic and biological agents","authors":"Ozcan Gul MD,&nbsp;Makbule Seda Bayrak Durmaz MD,&nbsp;Selma Yalcın MD,&nbsp;Aslı Bostanoglu Karacin MD,&nbsp;Sevim Bavbek MD","doi":"10.1016/j.waojou.2025.101065","DOIUrl":"10.1016/j.waojou.2025.101065","url":null,"abstract":"<div><h3>Background</h3><div>Rapid drug desensitization (RDD) for patients experiencing hypersensitivity reactions (HSRs) to chemotherapeutics and biological therapeutic agents allows for temporary tolerance to the implicated drug, since this procedure requires intensive labor and time, alternative single-bag RDD protocols have been developed. We aimed to share our experiences with single-bag and multi-bag RDD in patients with HSRs to chemotherapeutics and biological agents.</div></div><div><h3>Materials and methods</h3><div>Patients who were administered a single or three-bag RDD with implicated chemotherapeutics and biological agents between January 2020–August 2024 were included. The severity of HSRs was classified according to the Brown classification. Prick and intradermal tests were performed with the implicated drugs.</div></div><div><h3>Results</h3><div>A total of 153 patients (F:121, M:32, Mean age:56.7 ± 11.4) were included, 109 of whom had experienced HSRs to platinum, 37 to taxanes, and 7 to biological agents. The initial severity was mostly grade 2 (n:84,54.9%) or grade 3 (n:50,32.7%). Skin testings were positive in 70 of 139 patients tested. A total of 582 RDD procedures were performed to 76 patients with the single bag-12-step protocol and to 77 patients with the three-bag-12-step protocol. No statistically significant differences were found between the single-bag and three-bag groups regarding age, sex, atopy, presence of comorbidities, initial reaction severity, and skin test positivity. During the 582 RDD procedures, 44 breakthrough reactions (22 in each group) occurred. Ultimately, 581 out of 582 RDD procedures (99.8%) were successfully completed, except one patient with grade 2 reaction in the single-bag group. The desensitization procedures were completed in 273 ± 42 min for the single-bag group and in 367 ± 33 min for the three-bag group (p-value &lt;0.001).</div></div><div><h3>Conclusions</h3><div>Our study demonstrated that the single-bag protocol is as safe and effective as the three-bag protocol, while also providing a time-saving advantage. Thus, it is considered a viable alternative to multi-bag desensitization protocols.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101065"},"PeriodicalIF":3.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of three novel mite allergens, Der f 42, Der f 43, and Der f 44, from Dermatophagoides farinae by gelsolin interactome analysis","authors":"Ze-Lang Cai MSc ,&nbsp;Shan Liu BSc ,&nbsp;Anyi Ji BSc ,&nbsp;Rongfei Zhu MD, PhD ,&nbsp;Jia-Jie Chen PhD ,&nbsp;Kunmei Ji PhD","doi":"10.1016/j.waojou.2025.101067","DOIUrl":"10.1016/j.waojou.2025.101067","url":null,"abstract":"<div><h3>Background</h3><div>House dust mites (HDMs) produce major inhaled allergens that trigger allergic diseases worldwide. The identities of the full spectrum of HDM allergenic components are not yet known. We aimed to develop a new gelsolin interactome-analysis (GIA) method for discovering and identifying novel allergens.</div></div><div><h3>Methods</h3><div>Gelsolin-binding proteins (GBPs) in <em>Dermatophagoides farinae</em> extracts were analyzed with gelsolin-affinity resin and LC-MS/MS (liquid chromatography coupled to tandem mass spectrometry) analyses. Recombinant proteins generated from cDNAs encoding candidate allergens were expressed in a prokaryotic system. IgE binding was evaluated by ELISA (enzyme-linked immunosorbent assay), western blotting, and dot-blotting.</div></div><div><h3>Results</h3><div>A total of 14 GBPs were assayed, including 10 known allergens and 4 candidates. Three candidates bound recombinant gelsolin, and they were named Der f 42, Der f 43, and Der f 44 by the WHO/IUIS Allergen Nomenclature Sub-committee. IgE-binding assays showed that Der f 42, Der f 43, and Der f 44 had IgE-binding rates of 7.2% (9/125), 8.5% (12/143), and 6.7% (6/90), respectively.</div></div><div><h3>Conclusion</h3><div>GIA revealed 3 novel HDM proteins in this study and represents a new strategy for discovering and studying allergens.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101067"},"PeriodicalIF":3.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving asthma outcomes in Kuwait through a standardized emergency department algorithm","authors":"Mona Al-Ahmad MD ,&nbsp;Alyah Ebrahim MD ,&nbsp;Fatema Al Kandari MD ,&nbsp;Hanan Al Razzuqi MD ,&nbsp;Mohamed Al Shammari MD ,&nbsp;Naser Behbehani MD ,&nbsp;Nawaf Fahad Dehrab MD ,&nbsp;Rasha Buhumaid MD","doi":"10.1016/j.waojou.2025.101070","DOIUrl":"10.1016/j.waojou.2025.101070","url":null,"abstract":"<div><div>Asthma is a common chronic inflammatory disease of the respiratory system that significantly affects the quality of life and overall health of patients. When asthma is poorly managed, the risk of exacerbation and hospitalization increases, leading to higher direct and indirect healthcare costs and reduced productivity. Overuse of short-acting beta-agonists (SABAs) and underuse of inhaled corticosteroids (ICS) often result in poor asthma control and ineffective treatment. To reduce the frequency of exacerbation and alleviate pressure on Kuwait's healthcare system, it is important that patients are discharged with an evidence-based treatment plan.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101070"},"PeriodicalIF":3.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}